Maximizing binary interactome mapping with a minimal number of assays by Choi, S.G. et al.
  1 
 
Maximizing binary interactome mapping with a minimal 
number of assays 
 
Soon Gang Choi1-3,14, Julien Olivet1-4,14, Patricia Cassonnet5,14, Pierre-Olivier Vidalain6,14, Katja 
Luck1-3, Luke Lambourne1-3, Kerstin Spirohn1-3, Irma Lemmens7,8, Mélanie Dos Santos5, Caroline 
Demeret5, Louis Jones9, Sudharshan Rangarajan1-3, Wenting Bian1-3, Eloi P. Coutant10, Yves L. 
Janin10, Sylvie van der Werf5, Philipp Trepte11,12, Erich E. Wanker11, Javier De Las Rivas13, Jan 
Tavernier7,8, Jean-Claude Twizere4, Tong Hao1-3, David E. Hill1-3, Marc Vidal1,2★, Michael A. 
Calderwood1-3★, and Yves Jacob1,5★ 
 
 
1Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute (DFCI), 450 Brookline Avenue, 
Boston, MA 02215, USA. 2Department of Genetics, Blavatnik Institute, Harvard Medical School (HMS), 77 
Avenue Louis Pasteur, Boston, MA 02115, USA. 3Department of Cancer Biology, Dana-Farber Cancer Institute, 
450 Brookline Avenue, Boston, MA 02215, USA. 4Laboratory of Viral Interactomes, Unit of Molecular Biology 
of Diseases, Groupe Interdisciplinaire de Génomique Appliquée (GIGA Institute), University of Liège, 7 Place du 
20 Août, 4000 Liège, Belgium. 5Département de Virologie, Unité de Génétique Moléculaire des Virus à ARN 
(GMVR), Institut Pasteur, UMR3569, Centre National de la Recherche Scientifique (CNRS), Université Paris 
Diderot, Sorbonne Paris Cité, 28 rue du Docteur Roux, 75015 Paris, France. 6Équipe Chimie, Biologie, 
Modélisation et Immunologie pour la Thérapie (CBMIT), Laboratoire de Chimie et Biochimie Pharmacologiques 
et Toxicologiques (LCBPT), Centre Interdisciplinaire Chimie Biologie-Paris (CICB-Paris), UMR8601, CNRS, 
Université Paris Descartes, 45 rue des Saints-Pères, 75006 Paris, France. 7Center for Medical Biotechnology, 
Vlaams Instituut voor Biotechnologie (VIB), 3 Albert Baertsoenkaai, 9000 Ghent, Belgium. 8Cytokine Receptor 
Laboratory (CRL), Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent 
University, 3 Albert Baertsoenkaai, 9000 Ghent, Belgium. 9Centre de Bioinformatique, Biostatistique et Biologie 
Intégrative (C3BI), Institut Pasteur, 28 rue du Docteur Roux, 75015 Paris, France. 10Département de Biologie 
Structurale et Chimie, Unité de Chimie et Biocatalyse, Institut Pasteur, UMR3523, CNRS, 28 rue du Docteur 
Roux, 75015 Paris, France. 11Neuroproteomics, Max Delbrück Center for Molecular Medicine, 10 Robert-Rössle-
Str., 13125 Berlin, Germany. 12Brain Development and Disease, Institute of Molecular Biotechnology of the 
Austrian Academy of Sciences (IMBA), 3 Dr. Bohr-Gasse, 1030 Vienna, Austria. 13Cancer Research Center 
(CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca 
(USAL), Campus Miguel de Unamuno, 37007 Salamanca, Spain. 14These authors contributed equally: Soon Gang 
Choi, Julien Olivet, Patricia Cassonnet, Pierre-Olivier Vidalain. 
★e-mail: marc_vidal@dfci.harvard.edu; michael_calderwood@dfci.harvard.edu; yves.jacob@pasteur.fr 
.CC-BY-NC-ND 4.0 International licenseis made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It. https://doi.org/10.1101/530790doi: bioRxiv preprint 
  2 
ABSTRACT 
 
Complementary assays are required to comprehensively map complex biological entities such as 
genomes, proteomes and interactome networks. However, how various assays can be optimally 
combined to approach completeness while maintaining high precision often remains unclear. 
Here, we propose a framework for binary protein-protein interaction (PPI) mapping based on 
optimally combining assays and/or assay versions to maximize detection of true positive 
interactions, while avoiding detection of random protein pairs. We have engineered a novel 
NanoLuc two-hybrid (N2H) system that integrates 12 different versions, differing by protein 
expression systems and tagging configurations. The resulting union of N2H versions recovers as 
many PPIs as 10 distinct assays combined. Thus, to further improve PPI mapping, developing 
alternative versions of existing assays might be as productive as designing completely new assays. 
Our findings should be applicable to systematic mapping of other biological landscapes.   
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Complex biological entities such as genomes, proteomes and interactome networks require 
multiple, orthogonal approaches to be fully characterized. Even in the case of DNA, a highly 
homogenous macromolecule, sequencing and assembly of large genomes such as the human genome 
requires combinations of complementary methodologies including short-read sequencing as those 
provided by Illumina platforms, long-read DNA sequencing as in PacBio and/or Nanopore technologies, 
and HiC-related chromatin mapping tools1.  
Because polypeptides are more heterogeneous and structurally complex macromolecules than 
DNA2, determining protein features at the scale of the whole proteome is considerably more challenging 
than characterizing nucleic acid sequences. For instance, to expand the detectable portion of a proteome 
by mass-spectrometry, negative peptide ionization approaches are necessary to complement canonical 
positive-mode strategies3. Another example is protein crystallization that often requires hundreds of 
different conditions to be tested, including combining parameters such as ionic strength, temperature, 
pH, salt, protein concentrations and others4. Structural proteomics, which determines protein structures 
at proteome-scale5 also requires a palette of technologies such as X-ray crystallography, nuclear 
magnetic resonance (NMR), and/or cryogenic electron microscopy (cryo-EM) to reasonably cover 
proteins and protein complexes of different sizes, solubilities, and flexibilities6,7.  
In short, the mapping of large macromolecular landscapes usually requires multiple technologies 
that can be combined to complement each other’s relative shortcomings. However, for most 
comprehensive mapping projects, it remains unknown how to optimally combine various experimental 
methods in order to achieve maximal detection and specificity by a minimal number of assays.  
Macromolecules including DNA, RNA and proteins do not work in isolation but assemble into 
molecular machines, signaling cascades and metabolic pathways through interactions with other 
macromolecules, altogether forming complex interactome networks that are critical for biological 
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systems8,9. As protein-protein interactions (PPIs) play a pivotal role in these networks, it is essential to 
comprehensively identify binary PPIs10-12 and co-complex protein associations13-15, both at the scale of 
signaling pathways16,17, molecular machines18,19 and network modules20, and at the scale of the whole 
proteome12.  
Although medium- to high-throughput binary PPI detection assays have been available for three 
decades, since the original description of the yeast two-hybrid (Y2H) system21, it remains impossible to 
completely map interactome networks using any assay in isolation. This is well illustrated by the fact 
that most binary PPI assays developed so far only detect about a third of well-described benchmark 
interactions from a positive reference set (PRS) under conditions that limit, but not necessarily 
completely prevent, the detection of negative control protein pairs from a random reference set (RRS)22-
27. However, since different assays23 or assay versions28,29 often detect overlapping, yet distinct subsets 
of interactions, combining them should significantly increase overall detection. 
In order to comprehensively map binary PPIs both at the scale of signaling pathways and protein 
complexes and at the scale of whole proteomes, it should thus be possible to establish an optimal 
combination of assays and/or assay versions to capture nearly all interactions in a defined search space 
while ensuring high specificity (Fig. 1a). Our goal here was to systematically analyze experimental 
variables that influence binary PPI detection across multiple assays and integrate such knowledge into 
the rational design of a framework that maximizes detection with a minimal number of assays.  
We evaluated a class of binary PPI assays that are based on exogenously expressing pairs of 
hybrid proteins, collectively referred to as Tag1-X and Tag2-Y, where X and Y can be any protein, and 
Tag1 and Tag2 are two polypeptidic moieties, the physical proximity of which can be readily monitored. 
For example, in the Y2H system, X and Y interacting proteins restore physical proximity between the 
DNA binding domain (DB) and the activation domain (AD) of a transcription factor upon exogenous 
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expression of DB-X and AD-Y hybrid proteins21,30.  
In addition to assessing different assays defined by specific tag pairs, we also evaluated assay 
version differences due to: i) the relative orientation or swap of the tested proteins X and Y, 
differentiating between Tag1-X/Tag2-Y and Tag1-Y/Tag2-X; ii) the tagging configurations where we 
distinguish protein fusions from either the N- or C-terminal extremities of X and Y, e.g. Tag1-X/Tag2-Y 
versus X-Tag1/Y-Tag2; and iii) the exogenous expression systems, either in yeast, in mammalian cells, 
or in vitro (cell-free) (Fig. 1b).  
To uniformly compare these different experimental conditions within a single assay, we have 
engineered a PPI detection technology based on the functional reconstitution of NanoLuc, a small 
19kDa, high-performance bioluminescent protein31. Using this NanoLuc two-hybrid (N2H) system in 
combination with highly versatile vectors capable of driving protein expression as N- or C-terminal 
fusions of assay tags in all three environments, we show that permuting various experimental conditions 
in a single assay can achieve similar PPI detection as through the continuous addition of fundamentally 
different techniques (Fig. 1c). Our results suggest that only a few versatile assays should be sufficient to 
achieve near saturation with maximal precision in medium- and high-throughput proteome-scale PPI 
mapping projects. This finding might also be of value for large-scale mapping of other complex 
biological landscapes. 
 
RESULTS 
Combining binary PPI assays under maximized specificity 
Different binary PPI assays often detect distinct subsets of interactions23, thus combining several 
assays should increase the overall recovery in a given search space of the proteome (Fig. 1a). However, 
what remains unclear is how binary PPI assay combinations affect the overall specificity, i.e. the fraction 
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of true interactions detected in a given search space over the fraction of spurious pairs reported. 
Ten years ago, our group introduced an empirical framework to benchmark binary PPI assays 
based on: i) a list of ~100 well-documented positive control PPIs, constituting the first version of a PRS, 
or hsPRS-v1, ii) a list of ~100 pairs of proteins randomly picked among the ~2x108 pairwise 
combinations of human proteins, constituting version 1 of a RRS, or hsRRS-v122; and iii) the Gateway 
cloning of all open reading frames (ORFs) involved, allowing identical constructs to be used across 
many different assays33. We and others have since cross-examined the following binary PPI assays 
against each other: i) Y2H23, ii) yellow fluorescent protein-protein complementation assay (YFP-
PCA)23, iii) mammalian protein-protein interaction trap (MAPPIT)23, iv) well-based nucleic acid 
programmable protein arrays (wNAPPA)23, v) luminescence-based mammalian interactome 
(LUMIER)23, vi) kinase substrate sensor (KISS)25, vii) Gaussia princeps complementation assay 
(GPCA)24,34, viii) dual luminescence-based co-immunoprecipitation (DULIP)26, and ix) 
bioluminescence-based two-hybrid (LuTHy)27, combining bioluminescence resonance energy transfer 
(LuTHy-BRET) and luminescence-based co-precipitation (LuTHy-LuC) assays (Fig. 1c, left panel). 
Under the various conditions used in these studies, each of the corresponding 10 assays, 
representing the union of only one or two version(s) (Supplementary Table 1), recovered between 21% 
and 39% of hsPRS-v1 pairs, with the negative control hsRRS-v1 detection ranging between 0% and 4% 
(Supplementary Fig. 1a). However, to directly compare the different assays side-by-side and combine 
them homogeneously, an identical RRS threshold should be applied to each individual assay. After 
applying an identical RRS cutoff, increasing from 1% to 10%, to each of the above-mentioned assays, 
we observed that the union of the ten different assays detected between 70% and 91% of positive control 
hsPRS-v1 pairs with 8% and 59% of random hsRRS-v1 pairs scoring positive, respectively 
(Supplementary Fig. 1b). Therefore, to avoid accumulation of random pairs affecting the quality of 
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future analyses, each assay should be calibrated such that none of the RRS pairs are scored positive. 
After reanalyzing published data under these conditions, the recovered fractions of hsPRS-v1 pairs 
ranged from 3% to 33% for individual assays performed in only one or two version(s) (Fig. 2a), while 
the cumulative detection reached 65% when all assays were combined (Fig. 2b and Supplementary 
Fig. 1c). This suggested that many different assays, each associated to specific tag pairs and plasmids, 
would be needed to reach full coverage. 
 
Benchmarking binary PPI assays and assay versions 
We considered the possibility that the failure of the 10 assays described above (Fig. 2a,b) to 
detect nearly all PRS interactions might be due to ORF clone quality issues and/or problematic 
interaction annotations. To avoid such possibilities, we re-examined all protein pairs from the original 
reference sets: hsPRS-v1 and hsRRS-v123. As a first step, only fully sequence-verified, full length clonal 
ORFs were isolated (Supplementary Fig. 2a). Resulting pairs were then filtered based on updated 
literature information and annotations for binary PPIs (Supplementary Table 2). Finally, 60 PRS and 
78 RRS pairs were assembled into a second-generation of reference sets: hsPRS-v2 and hsRRS-v2, 
respectively (see Methods for details and Supplementary Fig. 2b). After repeating four assays that 
were originally benchmarked against hsPRS-v1 and hsRRS-v1 with the second generation of reference 
sets, the cumulative PRS recovery rate reached 50% and 58% with -v1 and -v2 sets respectively, when 
none of the RRS pairs were scored positive (Supplementary Fig. 2c).  
As the failure of 10 well-established assays to detect nearly all binary PPIs did not arise from 
problems with the original reference sets, we decided to evaluate whether expanding the number of 
experimental conditions, or assay versions (Fig. 1b), covered by any single technique could increase its 
coverage and ultimately reduce the number of assays required. To investigate this, we benchmarked 
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several versions of Y2H, MAPPIT, KISS and GPCA against the second-generation of reference sets, 
hsPRS-v2 and hsRRS-v2. These four assays and corresponding versions (10 in total) were implemented 
as summarized in Supplementary Table 1. In particular, we constructed Gateway-compatible vectors 
for GPCA to cover all four possibilities of tagging configurations with this assay, i.e. Tag1-X/Tag2-Y, 
X-Tag1/Tag2-Y, Tag1-X/Y-Tag2 and X-Tag1/Y-Tag2 or, simply, N1N2, C1N2, N1C2 and C1C2, 
respectively. Between 8% and 37% of hsPRS-v2 pairs were detected by the 10 versions of GPCA, 
MAPPIT, KISS and Y2H when none of the hsRRS-v2 pairs were scored positive (Fig. 2c), which 
represented an average PRS detection rate of 22.8% ± 8.8% (S.D.) (Fig. 2c, shaded blue area).  
When we considered all protein pairs identified by the union of these 10 versions corresponding 
to four assays, the hsPRS-v2 recovery rate reached 63% (Fig. 2d and Supplementary Fig. 2d), similar 
to what was obtained by combining ten distinct assays, performed in only one or two version(s), as 
published in the literature (65%; Fig. 2b). This result demonstrates that the combination of four distinct 
assays exploring different experimental conditions can recover as many PPIs as 10 fundamentally 
different techniques limited to a few versions. 
 
Towards developing a highly versatile binary PPI assay 
In an attempt to further minimize the overall number of multi-version assays required to 
maximize binary PPI detection and, by extension, reduce the associated cloning efforts and lab 
resources, we decided to develop a highly versatile binary PPI detection system opening access to all 
assay versions defined by the three experimental parameters presented in Fig. 1b.  
Although after re-analyzing published data 1.3-fold and 1.4-fold increases in PRS detection were 
observed when switching from one orientation to the other (i.e. Tag1-X/Tag2-Y to Tag1-Y/Tag2-X), or 
from one configuration to another (i.e. N1N2 to C1N2), respectively (Supplementary Fig. 3a,b), the 
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impact of permuting expression systems remained unclear as no assay had been used to systematically 
explore this parameter. However, several high quality PPI datasets have been obtained using 
heterologous expression of protein pairs in yeast12,35, in mammalian cells36,37 and via cell-free coupled 
transcription-translation systems in vitro38,39. 
After surveying existing binary interaction assays, it appeared that split-protein reconstitution 
was the most suitable technology to cover the three experimental parameters presented in Fig. 1b. 
Indeed, compared to other binary PPI methods involving cell-specific responses or antibody-based 
captures, split protein-based assays enable detection of PPIs through the simple reassembly of a 
functional reporter protein (Fig. 1c). Among the different reporters available today, NanoLuc, a highly-
stable 19kDa protein derived from the luciferase complex of the deep-sea shrimp O. gracilirostris, is 
gaining increasing attention for the development of binary PPI detection assays, as highlighted by recent 
publications31,32,40,41. Following the single-step addition of imidazopyrazinone substrates, NanoLuc 
instantly produces an intense and sustainable glow-type luminescence with a specific activity about 100-
fold greater than that of other luciferases, allowing its detection in vitro as well as in living cells and 
animals31,42,43. Therefore, split-NanoLuc-based technology appears to be the ideal candidate for the high-
throughput detection of binary PPIs in various experimental conditions.  
Among the recent studies reporting a split-NanoLuc binary PPI assay, only one extensively 
fragmented the enzyme to test different tag pairs in an unbiased way (Supplementary Table 3)32. After 
selecting a cleavage site between amino acids 156 and 157, the authors heavily modified the 
corresponding fragments to reduce their association affinity. The resulting moieties, 11S (156 amino 
acids) and 114 (11 amino acids), were then used to develop the NanoLuc Binary Technology (NanoBiT) 
assay32. 
Even though NanoBiT was originally designed for expression of protein pairs in mammalian 
.CC-BY-NC-ND 4.0 International licenseis made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It. https://doi.org/10.1101/530790doi: bioRxiv preprint 
  10 
cells, we decided to evaluate whether fragments 11S and 114 could be used to further develop our new, 
highly versatile binary PPI detection system (Fig. 1c, right panel). To investigate this, we first adapted 
the available NanoBiT vectors with the reported original split site32 to achieve different tagging 
configurations with Gateway cloning compatibility and then benchmarked all four pairing combinations, 
i.e. N1N2, C1N2, N1C2 and C1C2, against hsPRS-v2 and hsRRS-v2. The benchmarking of these four 
NanoBiT versions in conditions where none of the hsRRS-v2 pairs are scored positive showed that 
between 3% and 25% of hsPRS-v2 pairs could be recovered (Fig. 2c). These results revealed optimal 
performances when the larger NanoBiT fragment, 11S (156 amino acids), was fused to the C-terminal 
extremity of the tested proteins, as demonstrated by PRS recovery rates of 22% and 25% for the C1N2 
and C1C2 configurations, respectively, similar to those from four other well-established assays (Fig. 
2c). These observations were in agreement with the author’s original assumption that the C-terminus 
tagging of proteins with 11S might impose minimal steric constraints32.  
 
Nanoluc 2-Hybrid (N2H): a highly versatile binary PPI assay 
Although NanoBiT appears to be a powerful tool to study PPI kinetics in live cells, the 
comprehensive benchmarking of this assay revealed two underperforming versions, N1N2 and N1C2, 
that might be associated to the inherent properties of the selected tag pair32. Therefore, we decided to 
empirically define a new split site for NanoLuc in an unbiased way. To do this, we first extensively 
fragmented the full-length enzyme by transposon-based insertional mutagenesis (Supplementary Fig. 
4a). Complementation of the resulting fragments, F1 and F2 (58 pairs in total), was then systematically 
tested using a proximity assay in vitro (Supplementary Fig. 4b), and a cleavage site between amino 
acids 65 and 66 was selected (Fig. 3a) to build the NanoLuc 2-hybrid (N2H) assay (Fig. 1c, right panel 
and Supplementary Fig. 4c). 
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In order to comprehensively cover the experimental parameters presented in Fig. 1b with the 
single N2H assay, we constructed four Gateway-compatible plasmids from which N2H fragments, F1 
(amino acids 1-65) and F2 (amino acids 66-171), can be expressed as either N- or C-terminal fusions of 
any pair of proteins X and Y in yeast, in mammalian cells or in vitro (cell-free). To drive expression in 
all three environments with each individual plasmid, we engineered a tripartite promoter of ~1kb that 
can easily be introduced into any vector of interest (Fig. 3b). The performance of this 3-in-1 promoter 
was evaluated by measuring the expression of full-length and fragmented NanoLuc in yeast (yN2H), in 
mammalian cells (mN2H) and in vitro (vN2H). We obtained intense signals ranging between 108 and 
109 relative luminescence units (RLU) when the full-length NanoLuc was expressed in each individual 
environment. Furthermore, compared to the full-length enzyme, individually expressed NanoLuc 
fragments did not produce any significant signal. More importantly, the two fragments expressed 
together did not generate any strong self-assembly luminescence that could interfere with the accurate 
measurement of binary PPIs. Taken together, these results demonstrate the full functionality of both the 
tripartite promoter and the selected pair of NanoLuc fragments (Fig. 3b).  
By combining NanoLuc fragments with the tripartite promoter and Gateway-cloning technology 
into four uniform expression vectors (pDEST-N2H-N1, -N2, -C1 and -C2), all 24 assay versions 
(4x3x2) presented in Fig. 1b could thus be implemented with the single N2H assay. The Gateway-
compatibility of N2H destination plasmids also renders the entire human ORFeome collection of over 
18,000 entry clones44 directly amenable to this assay. 
As N2H was the first binary PPI detection tool in which proteins could be expressed as either N- 
or C-terminal fusions of protein tags in yeast (yN2H), in mammalian cells (mN2H) or in vitro (vN2H) 
from the same Gateway-compatible destination vector (Figs. 1b,c, 3b), it was important to benchmark 
the robustness of PPI-mediated readouts in each of the three environments. Using hsPRS-v2 and hsRRS-
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v2 pairs, we compared bioluminescence signals between two independently replicated experiments in 
yN2H, mN2H and vN2H. As highlighted by the R2>0.97, a robust reproducibility was observed in each 
case when all 138 pairs from hsPRS-v2 and hsRRS-v2 were tested. In addition, a large dynamic range of 
luminescence readout between 102 and 107 RLU was consistently observed in each environment (Fig. 
3c). 
To compare the performance of N2H assay versions in detecting reference binary PPIs over 
random protein pairs, we normalized luminescence signals and separated hsPRS-v2 from hsRRS-v2. No 
major differences were observed in the overall luminescence ratios as a fraction of PRS pairs always 
generated higher signals than that from random pairs in each case (Fig. 3d). As observed for C1C2-
mN2H or C1C2-yN2H, for example, the only differences in PRS detection rates between assay versions 
came from one or a few RRS pairs that generated higher luminescence signals than the average. These 
version-specific artifacts ultimately reduced the fraction of PRS pairs recovered as their corresponding 
thresholds of no RRS pair scoring positive increased (Fig. 3d). The same observation was also made for 
well-established assays (Fig. 2a,c). Thus, in conditions where none of the RRS pairs are scored positive 
(threshold displayed for each individual version in Fig. 3d), the 12 tested N2H assay versions detected 
between 7% and 32% of hsPRS-v2 pairs (Fig. 3e), demonstrating similar performances compared to five 
other PPI detection methods (Fig. 2c) that averaged 20.4% ± 9.9% (S.D.) PRS recovery (Fig. 3e, shaded 
blue area). When these 12 N2H versions were combined, a PRS detection of 60% was yielded (Fig. 3f 
and Supplementary Fig. 5a), similar to the 65% obtained by combining either 10 different, version-
limited assays from the literature23-28 (Fig. 2a,b) or five non-N2H, multi-version assays (Fig. 2c and 
Supplementary Fig. 5b).  
These results highlight the advantages of using a single, highly versatile PPI detection tool, such 
as N2H, to reduce the overall cloning efforts and lab resources (Fig. 4a-c), as the same set of expression 
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vectors are used to explore several assay versions at a time (Fig. 4d) whilst recovering as many PPIs as a 
combination of many different techniques (Fig. 4e). The published assays in Fig. 4 are presented in Fig. 
2a and Supplementary Table 1. 
 
Combining multi-version assays to maximize PPI detection 
With all assays in hand to systematically evaluate the impact of the three variables presented in 
Fig. 1b, we decided to combine the different PPI assay versions previously tested against the improved 
reference sets (Figs. 2c, 3e) in respect of each individual parameter. All analyses were conducted in 
conditions where none of the random pairs are scored positive. 
As the impact of permuting proteins X and Y from one tag to the other (Tag1-X:Tag2-Y versus 
Tag1-Y:Tag2-X) had already been comprehensively investigated by six different assays in the 
literature23,26,27 (Supplementary Table 1), we only repeated Y2H and MAPPIT to explore this 
parameter. While a single, randomly picked orientation yielded PRS recovery rates of 19% and 32%, 
switching to the second orientation increased detection to 25% and 40% for Y2H and MAPPIT, 
respectively. Importantly, cumulative PPI detection increased from 38% to 47% when a single or two 
orientations were combined for both assays, respectively (Fig. 5a). This 1.2-fold (47/38) increase was 
consistent with our analysis of published results23,26,27 (Supplementary Fig. 3a) and confirmed that 
permuting the orientation of tested proteins is a valuable option to increase PPI detection. 
To probe the influence of different tagging configurations on PPI detection, i.e. the N- or C-
terminal positioning of the assay tags, we systematically evaluated the contribution of each pairing 
combination (N1N2, C1N2, N1C2 and C1C2) with KISS, NanoBiT, GPCA, mN2H, yN2H and vN2H. 
For KISS, the analysis was restricted to the two published configurations: N1N2 and C1N225. Using 
mN2H as a first example, we observed an average PRS detection rate of 19% for a single, randomly 
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picked tagging configuration (Fig. 5b). When two of the four possible tagging configurations were used, 
the PRS recovery rate was further increased to 28%. Finally, when three and all four tagging 
configurations were combined, 34% and 37% of hsPRS-v2 pairs were identified (Fig. 5b). Thus, using 
more than one tagging configuration substantially increased the detection of binary PPIs by mN2H. 
Similar observations were made for the other assays as the PRS recovery rates were increased from an 
average 26% to 42% for KISS, where only two configurations were tested, and from 14% to 28% for 
NanoBiT, 19% to 35% for GPCA, 21% to 45% for yN2H and 19% to 33% for vN2H when only one or 
all four configurations were tested, respectively. The same trend was observed when combining all 
tested versions and a 1.6-fold increase in PRS detection obtained by extending assays from a single to 
multiple configurations (Fig. 5b, union). These results illustrate the gain of sensitivity achieved when 
performing the same assay with different combinations of tagging configurations, and confirm the 
preliminary observations made after re-analyzing published data23,25 (Supplementary Fig. 3b).  
To evaluate the impact of different protein expression systems on binary PPI detection, we 
implemented different versions of the N2H assay in yeast, in mammalian cells and in vitro (cell-free). 
All four tagging configurations (Fig. 1b,c) were systematically tested in each environment. For the 
N1N2 version, an average PRS detection rate of 24% was reached when performing the assay in a single 
environment. This recovery was increased to 35% when switching to a second expression environment. 
Finally, after combining detected PRS pairs from all three environments, the cumulative recovery rate 
reached 42% for the N1N2 versions of N2H (Fig. 5c). When we expanded the analysis to the other 
tagging configurations, N1C2, C1C2, and C1N2, we consistently observed that performing the assay 
with different expression systems allowed the identification of a larger fraction of PPIs (Fig. 5c). Indeed, 
a robust growth of cumulative PRS detection was observed for N1C2 (from 18% to 40%), C1C2 (from 
11% to 22%) and C1N2 (from 24% to 43%) when PPIs were tested in just one or all three different 
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expression environments, respectively. Importantly, the cumulative PPI recovery rate for all 12 N2H 
assay versions tested here was increased from 38% to 60% when using one or all three expression 
systems, respectively, which represented an overall 1.6-fold increase in PPI detection (Fig. 5c, union). 
This result also highlights that the performance of the single multi-version N2H assay (60% PRS 
recovery) was significantly higher than that of any other method presented in this study (Fig. 2a,c).  
Taken together, these observations demonstrate the benefit of permuting experimental conditions 
in binary PPI assays to increase detection (Fig. 5a-c). What remained unclear was the overall 
complementarity of assay versions when they are all combined. To visualize the different subsets of 
interactions recovered by the six different assays analyzed in this study (Figs. 2c, 3e), we displayed the 
performance of their corresponding 26 assay versions in the form of a checkerboard plot. Under 
conditions where none of the hsRRS-v2 pairs are scored positive, the different versions detected distinct 
but partially overlapping subsets of PPIs, the union of which reached 78% (Fig. 6). Importantly, as 
already observed in Fig. 3f, the combination of 12 N2H versions detected 60% of PRS pairs, which 
means that this single assay recovered over three-quarters of all PPIs detected in this study (Fig. 6). 
Taken together, these results showed that a single assay exploring multiple dimensions of the parameter 
space (Fig. 1b,c) will be sufficient to map a large fraction of binary PPIs in a defined search space.  
 
DISCUSSION 
Over the past ten years, the community has continuously released new binary PPI detection tools. 
The benchmarking of these assays, using a first generation of positive (hsPRS-v1) and random (hsRRS-
v1) reference sets, revealed that they often identify distinct subsets of interactions23. Therefore, a 
combination of multiple techniques will be required to increase overall PPI detection and reach 
completeness (Fig. 1a). Under conditions of optimal specificity, we have shown that no single PPI assay 
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is exceptionally superior to any other, including the most recently developed technologies. Furthermore, 
we have established that instead of continuously developing fundamentally different techniques, it 
should be possible to reach completeness by assembling a minimal number of binary PPI assays, as long 
as different experimental conditions, or assay versions, can be implemented for each selected assay 
(Figs. 1b,c).  
We eliminated the possibility that the failure of 10 combined assays to detect about a third of 
known interactions in the original hsPRSv1 came from ORF clone quality issues or problematic 
interaction annotations by benchmarking assays against an improved, unbiased22 second-generation of 
reference sets: hsPRS-v2 and hsRRS-v2. Although the improvement of reference sets was purely 
focused on pair quality in this study, the next generation of PRS and RRS should include larger fractions 
of interactions such as those involved in higher order complex structures as well as interactions from co-
complex crystal structures where direct contacts are well defined. Protein pairs for which a variety of KD 
measurements are available27 will also be included to characterize assays and assay versions according 
to their capabilities of recovering interactions of different strengths. 
Using the improved standards under conditions that maximized specificity, we have shown that 
considering three experimental parameters, i.e. protein orientation, tagging configuration and expression 
system (Fig. 1b), for assay development is a valuable option to increase PPI detection. In particular, we 
demonstrated that combining a relatively small number of assays exploring these parameters could lead 
to a PPI detection rate of up to 78%. In this context, we showed that combining 12 different versions of 
N2H, a new, highly versatile split NanoLuc-based assay, could recover 60% of all positive control 
interactions, similar to the 65% recovery rates obtained by combining either 10 published version-
limited assays or four distinct multi-version assays. This means that the highly versatile N2H assay 
identified 77% of all PPIs detected in this study. In short, our results highlight the advantage of N2H or 
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similar versatile systems, capable of handling several experimental parameters in a single, multi-version 
toolkit, to improve PPI detection and ultimately reduce the number of binary PPI assays required. This 
also suggests that only a few versatile binary PPI assays will be sufficient to reach complete coverage of 
any defined search space. 
Surprisingly, 22% of hsPRS-v2 pairs remained undetected after combining the six assays tested 
in this study, even though all interactions had similar numbers of experimental evidence and 
publications (Supplementary Fig. 6). We examined whether there was any correlation between a tested 
PPI assay in this study, and the original detection method54 of the PRS pairs, but we did not find any 
correlation between these two elements. In two cases, the ORFs we used corresponded to shorter 
isoforms that did not contain reported interaction domains (Supplementary Table 5). Upon removal of 
these two ORFs, the PRS recovery rate by the union of all 26 assay versions yields 81%. However, two 
thirds of undetected hsPRS-v2 pairs contained reported interaction domains. Therefore, to reach 
completeness, we suggest that future assay development should be focused on expanding the number of 
versions covered by already-existing techniques. In that regard, we have extended our finding to the 
recently developed LuTHy assay27 and validated our original conclusions as additional PRS detection 
was observed when running all 16 versions (2 environments x 2 orientations x 4 configurations) allowed 
by this technology (data not shown). In addition, exploring yet untouched experimental parameters such 
as additional modifications of tag-protein fusions, or alternative expression environments including sub-
cellular localization should also help reaching full coverage.  
Given the difficulties of performing heterogeneous PPI assays with the necessity of preparing 
different clones for expression vectors and setting up different experiments, performing an equal number 
of N2H assay versions to acquire comparable PPI detection offers a valuable alternative to reduce these 
efforts (Fig. 4a-e). 
.CC-BY-NC-ND 4.0 International licenseis made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It. https://doi.org/10.1101/530790doi: bioRxiv preprint 
  18 
The fact that expression environment has a strong impact on PPI detection is particularly 
interesting as it can easily be tuned with N2H or similar versatile assays. For example, protein pairs 
could be expressed in multiple cell lines, including distinct cell types and tissue origins, while a range of 
pH or salt concentrations could easily be tested when performing the assay in vitro. From a single set of 
plasmids, this would open access to almost unlimited assay versions to generate near-complete, high-
quality binary interactome maps in a more time-effective manner. 
  
METHODS 
Processing publicly available hsPRS-v1 and hsRRS-v1 data. Publicly available protein interaction 
datasets used in this study came from the original publications23,24,26 or were provided by the authors 
upon request25,27. Analyses were restricted to datasets for which a straightforward titration at a threshold 
of no RRS pair scoring positive could be applied. To evaluate the recovery rates of hsPRS-v1 when none 
of the RRS pairs are scored positive, data were calibrated such that the provided score for a given PRS 
pair must be strictly higher than the highest score of any of the RRS pairs. When authors clearly 
identified a particular pair as not interacting (negative) in their experiments, this assignment was also 
considered to generate the final dataset at a threshold where no RRS pair was scored positive. The same 
criterion was applied to evaluate the fractions of pairs found with available assay permutations, by using 
the highest RRS score found in each independent version of the corresponding assay. 
 
Construction of hsPRS-v2 and hsRRS-v2 reference sets. Second-generation hsPRS-v2 (60 pairs) and 
hsRRS-v2 (78 pairs) were constructed from pre-existing hsPRS-v1 (92 pairs) and hsRRS-v1 (92 pairs)23. 
To update the v1 sets generated over 10 years ago, we first decided to obtain single colony isolates for 
each ORF clone, removing all possible mutations that could have appeared in the original mini-pool 
ORFeome collection11,45. Each entry clone passed through multiple rounds of individual single colony 
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isolations, plasmid DNA purifications, and Sanger DNA sequencings, and only full-length, fully 
sequence-verified clones (next generation sequencing) were selected. By comparing the ORF sequences 
with genome annotations, we removed ORFs that did not match annotations in Gencode 2746, resulting 
in 76 PRS pairs and 78 RRS pairs (91.8% success rate at the ORF level, Supplementary Fig. 2a). We 
further inspected the remaining 76 PRS pairs by literature mining and informatics filtering. We revisited 
the supporting evidence for each PRS pair using an updated classification of binary PPI detection 
methods (Supplementary Data 1). For example, pull down and co-immunoprecipitation are no longer 
considered as binary PPI detection methods12. Ten PRS pairs not satisfying binary classification were 
removed. Three PRS pairs containing HLA proteins were also discarded, as no reference ORF could be 
defined. Finally, three PRS pairs between precursor ligands (FGF1, CXCL1, and TNFSF10) and their 
respective receptors were also removed due to the requirement of proteolytic cleavages of the ligands for 
maturation (Supplementary Table 2 and Supplementary Fig. 2b). After applying these filters, at total 
of 60 PRS pairs and 78 RRS pairs were thus assembled into hsPRS-v2 and hsRRS-v2, respectively 
(Supplementary Table 4). Discarded pairs from hsPRS-v1 and hsRRS-v1 are presented in 
Supplementary Data 1, and PubMed IDs supporting remaining hsPRS-v2 pairs are presented in 
Supplementary Data 2. The performances of the updated reference sets were compared to the older sets 
by repeating four assays previously benchmarked with hsPRS-v1 and hsRRS-v1 (Supplementary Fig. 
2c). 
 
Cloning ORFs into Gateway-compatible expression plasmids. Human hsPRS-v2 and hsRRS-v2 
ORFs are available in pDONR221 or pDONR223 vectors, which make them compatible with the 
Gateway cloning technology. Each ORF was introduced into the different assay-specific expression 
vectors used in this study via an LR clonase-mediated Gateway reaction (Life Technologies). LR 
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reaction products were subsequently transformed into DH5α competent bacterial cells and grown for 24 
hours in ampicillin-containing TFB liquid medium. Plasmid DNA was extracted using a NucleoSpin 96 
Plasmid kit from Macherey-Nagel. After PCR-amplification using plasmid-specific primers, the size of 
each DNA amplicon was examined by agarose gel electrophoresis. For each batch of ready-to-go 
destination vectors, DNA sequencing was performed on a subset of the cloned samples to check the 
quality of cloning before running the PPI assays. 
 
Construction of the tripartite promoter and N2H plasmids. The design of the 3-in-1 hybrid promoter 
was based on the recent description of highly potent, minimal synthetic promoters in yeast S. 
cerevisiae47. These promoters comprise a short synthetic upstream activating sequence (UAS) and 
generic core elements, including a TATA box and a Transcription Start Site (TSS). The average distance 
separating the UAS motif upstream of the TATA box in native yeast and mammalian cell promoters was 
sufficient to insert the GC boxes and the CCAAT box-binding transcription factor (CTF) binding site of 
the herpes simplex virus-thymidine kinase (HSV-TK) promoter48 between these two elements. To boost 
expression levels in mammalian cells, the cytomegalovirus (CMV) immediate early enhancer was 
inserted upstream of the yeast synthetic UAS. To drive expression in vitro using a coupled 
transcription/translation system, a T7 promoter was inserted 30 nucleotides downstream of the TATA 
box, immediately followed by a cricket paralysis virus internal ribosome entry site (CrPV-IRES), a 
versatile IRES used to initiate translation in both, mammalian and yeast cells49,50. All these regulatory 
elements were assembled using gene synthesis (GenScript) and 40 nucleotides of sequence homology to 
the insertion sites in the vector backbone (pESC-LEU, Agilent, cat #217452; pESC-TRP, Agilent, cat 
#217453) were added for gap repair recombination in yeast51,52. NanoLuc fragments, F1 (1-65) and F2 
(66-171), were linked to either the N-terminal (pDEST-N2H-N1, -N2) or C-terminal (pDEST-N2H-C1, 
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-C2) extremity of the tested protein, using a flexible hinge encoding a polypeptide of 20 amino acids 
along with Gateway recombinational cloning sites. Finally, expression levels in the different systems 
were assessed using full length or fragmented NanoLuc (Promega, cat #N1001) reporter genes (Fig. 3b). 
 
Systematic evaluation of NanoLuc fragments complementation. NanoLuc fragments, were 
systematically generated by transposon-based insertional mutagenesis randomly distributed between 
nucleotides 55 and 249 of the NanoLuc coding sequence, corresponding to amino acid residues 19 and 
83, respectively (Supplementary Fig. 4a). Resulting moieties were characterized by Sanger DNA 
sequencing using pMOD forward and reverse primers according to the manufacturer’s protocol (EZ-
Tn5, epicentre-Illumina, #TNP10622). Each fragment was then subcloned into a specifically designed 
SNAP-Tag in vitro expression vector, using Gateway recombination cloning (Life Technologies). They 
were expressed using a human IVT in vitro system and their complementation was assessed using a 
proximity-based assay. 
 
Design of the SNAP-Tag in vitro expression vector. DNA encoding the SNAP-Tag was PCR-
amplified from the pSNAPf vector (NEBs, #N9183S) to be inserted in frame into the pT7CFE1-CHis 
plasmid provided in the human IVT kit (ThermoFisher, #88882). The Gateway cloning cassette was 
introduced immediately after the SNAP tag sequence using the Gateway vector conversion system 
(Invitrogen, # 11828-029). All subsequent cloning steps were performed using Gateway BP and LR 
reactions according to the manufacturer’s protocol. DNA constructs were prepared using standard maxi- 
and mini-prep protocols. 
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Human IVT in vitro expression system. To assess complementation of NanoLuc fragments, a HeLa 
cell lysate was used for in vitro-coupled transcription and translation (IVT system, ThermoFisher, 
#88882). All the reactions were performed according to the manufacturer’s protocol, except for DNA 
concentrations (150 ng for both expression vectors were used) and the use of a 5x dilution of the HeLa 
cell lysate in the DB buffer. Concentrated DB buffer (10x) consisted in 540 mM HEPES-KOH pH: 7.6; 
800 mM K-acetate; 40 mM Mg-acetate; 50 mM DTT; 5 mM Spermidine; 12.5 mM ATP and 200 mM 
Creatine phosphate. The final mixture containing the diluted HeLa cell lysate with the accessory 
proteins and the manufacturer’s reaction buffer was supplemented with 0.8 mM UTP, CTP; 1.2 mM 
GTP, and 50 µM of each amino acid (Promega, #L446A). T7 RNA polymerase (NEBs, #MO251L) were 
added at a final concentration of 1 unit/µL. Reaction was performed for 90 minutes at 30°C, directly in 
96 or 384-well plates.  
 
In vitro proximity assay based on SNAP-tag capture. NanoLuc fragments fused to SNAP-tags were 
expressed in the human IVT system and assayed for complementation by generating a Biotin-
Streptavidin complex. After IVT expression, the reaction mixture was incubated for 30 min at 30°C with 
1 µL/well of a 250 µM SNAP-biotin substrate dilution in fresh DMSO. Streptavidin-biotin complexes 
were further generated by adding 1 µL/well of 1 mg/mL of streptavidin solution (Sigma-Aldrich, 
#85878). The reconstituted luciferase enzymatic activity was monitored by injecting 50 µL/well of the 
Nano-Glo reagent (Promega, #N1120). 
 
Mammalian cell-based version of N2H assay (mN2H). HEK293T cells were seeded at 6x104 cells per 
well in 96-well, flat-bottom, cell culture microplates (Greiner Bio-One, #655083), and cultured in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum at 37°C and 5% 
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CO2. 24 hours later, cells were transfected with 100 ng of each N2H plasmid (pDEST-N2H-N1, -N2, -
C1 or -C2) using linear polyethylenimine (PEI)46 to co-express the protein pairs fused with 
complementary NanoLuc fragments, F1 and F2. The DNA/PEI ratio used for transfection was 1:3 
(mass:mass). 24 hours after transfection, the culture medium was removed and 50 µL of 100x diluted 
NanoLuc substrate (Promega, #N1110) was added to each well of a 96-well microplate containing the 
transfected cells. Plates were incubated for 3 minutes at room temperature. Luciferase enzymatic activity 
was measured using a TriStar or CentroXS luminometer (Berthold; 2 seconds integration time). 
The stock solution of PEI HCl (PEI MAX 40000; Polysciences Inc; Cat# 24765) was prepared 
according to the manufacturer’s instructions. Briefly, 200 mg of PEI powder added to 170 mL of water, 
stirred until complete dissolution, and pH was adjusted to 7 with 1 M NaOH. Water was added to obtain 
a final concentration of 1 mg/mL, and the stock solution was filtered through a 0.22 µm membrane. 
 
Yeast cell-based version of N2H assay (yN2H). Using a high-efficiency LiAc/SS carrier DNA/PEG 
protocol53, haploid S. cerevisiae Y8800 (MATa, leu2-3,112 trp1-901, his3Δ200, ade2-101 ura3-52, 
gal4Δ, gal80Δ, chy2R, GAL2::ADE2, GAL7::LacZ@met2, GAL1::HIS3@LYS2) and Y8930 (MATα, 
leu2-3,112 trp1-901, his3Δ200, ade2-101 ura3-52, gal4Δ, gal80Δ, chy2R, GAL2::ADE2, 
GAL7::LacZ@met2, GAL1::HIS3@LYS2) yeast strains were transformed with pDEST-N2H plasmids 
(pDEST-N2H-N1, -N2, -C1 and –C2) containing a TRP1 (N2/C2/Fragment 2 vectors) or a LEU2 
(N1/C1/Fragment 1 vectors) cassette, respectively. For each individual transformation, 0.3 to 1.5 µg of 
high-purity plasmid and 1 mL of log phase yeast cell culture (OD600 nm ~ 0.6-0.9) were used. The 
resulting transformants carrying N2/C2/Fragment2 vectors (TRP1 cassette) or N1/C1/Fragment1 vectors 
(LEU2 cassette) were spotted (8 µL per spot) onto solid synthetic complete media lacking tryptophan 
(SC-W) or leucine (SC-L), respectively. After 3 days of incubation at 30°C, each transformant growing 
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on solid SC-W or SC-L was picked by scratching the corresponding spot and inoculated into a 96-well 
microplate (Fisher Scientific/Corning, #07200720A) containing 160 µL of liquid SC-W or SC-L per 
well, respectively. Inoculated yeast cells were incubated overnight (15 to 18 hours), at 30°C and under 
shaking conditions (220 rpm). Haploid yeast were mated by inoculating 5 µL of transformed MATa 
Y8800 and 5 µL of transformed MATα Y8930 into a 96-well microplate containing 160 µL of YEPD 
medium (yeast extract, peptone, dextrose) per well. Mating was obtained by growing cells overnight (15 
to 18 hours), at 30°C and under shaking conditions (220 rpm). A first diploid selection was conducted 
by inoculating 10 µL of mated yeast cells into a 96-well microplate containing 160 µL of SC-LW 
medium per well. Cells were incubated overnight (15 to 18 hours), at 30°C and under shaking conditions 
(220 rpm). A second diploid selection was conducted by inoculating 50 µL from the first diploid 
selection culture into a 96-well deep well plate (QIAGEN, #19579) containing 1.2 mL of liquid SC-LW 
medium per well. Diploids were grown by incubating cells for 24 hours, at 30°C and under shaking 
conditions (900 rpm). Cell density was determined by transferring 100 µL of each diploid cell culture 
into individual wells of a 96-well microplate and measuring OD600 nm with a microplate reader 
(optional). Deep well plates containing diploid yeast cells were centrifuged at 2,500g for 15 minutes. 
After centrifugation, the supernatant was discarded and residual SC-LW medium removed by gently 
blotting deep well plates with absorbent paper. Each yeast cell pellet was individually resuspended into 
100 µL of the NanoLuc Assay solution by gently pipetting up-and-down several times, until cell pellets 
were fully dispersed. Homogenized solutions were transferred into white flat-bottom 96-well plates 
(Greiner bio-one, cat# 655073) that were then sealed with aluminum foil and incubated for one hour at 
room temperature. After incubation, plates were shaken for 30 seconds at 950 rpm to resuspend yeast 
cells. Using a luminometer (Berthold) set up for one-second orbital shaking before each measurement 
(speed: fast; diameter: 5 mm), luminescence was evaluated for each reaction. Integration time of the 
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luminescence signal was set at 2 seconds per sample. 
 
In vitro version of N2H assay (vN2H). Synthesis of proteins was performed separately using the in 
vitro coupled transcription-translation system based on Insect Cell Extract (ICE) (TnT-T7-ICE, 
Promega, #L1102). In this ICE coupled transcription-translation system, transcription is driven by T7 
RNA-Polymerase present in the ICE reagent. The necessary T7 promoter is included in the N2H 
synthetic promoter as described in Fig. 3b. Each reaction was performed in 25 µL final volume with 1 
µg of pDEST-N2H plasmid (5 µL at 200 ng/µL) and 20 µL of diluted insect cell extract (containing 4 
µL of ICE, 3.2 µL of 5x ICB dilution buffer and 8 units of T7-RNAP-Promega#P4074, supplemented 
with H2O up to 20 µL). Incubation was at 30°C for 4 hours. The synthesis reaction was stopped by 
addition of 50 µL of 1x PBS  (Gibco, #14190-094) containing 20% glycerol (for storage at -80°C). The 
NanoLuc assay was carried out in 96-well format by mixing 5 µL of each in vitro synthesized protein 
with 15 µL of 1x PBS per well. After incubation at 30°C for 90 minutes, 50 µL of 100x diluted 
NanoLuc substrate (Promega, #N1110) were added, and luciferase enzymatic activity was measured 
using a TriStar or CentroXS luminometer (Berthold; 5 seconds integration time). 
Concentrated insect cell buffer (ICB 5x) consists of 150 mM HEPES-KOH pH: 7.6; 750 mM K-
acetate; 19.5 mM Mg-acetate; 12.5 mM DTT; 500 µM spermidine; 100 mM creatine phosphate; 0.5 
mg/mL creatinine kinase; 8.75 mM ATP; 1.5 mM GTP, CTP, UTP and 500 µM amino acids mix. The 
stock solution of amino acids (3.4 mM) was made by dissolving the 20 powders into 5 M KOH, at 
concentrations ranging from 1.6 to 4 M. The resulting mixtures containing each of the 20 amino acids 
were diluted in water to achieve a final concentration of 238 mM. The final aqueous solution was 
adjusted to pH 7.5 with acetic acid, diluted to 3.4 mM and frozen in liquid nitrogen for storage at -80°C. 
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Yeast 2-Hybrid (Y2H) assay. Using a high-efficiency LiAc/SS carrier DNA/PEG protocol53, haploid S. 
cerevisiae Y8800 (MATa, leu2-3,112 trp1-901, his3Δ200, ade2-101 ura3-52, gal4Δ, gal80Δ, chy2R, 
GAL2::ADE2, GAL7::LacZ@met2, GAL1::HIS3@LYS2) and Y8930 (MATα, leu2-3,112 trp1-901, 
his3Δ200, ade2-101 ura3-52, gal4Δ, gal80Δ, chy2R, GAL2::ADE2, GAL7::LacZ@met2, 
GAL1::HIS3@LYS2) yeast strains were transformed with pDEST-AD and pDEST-DB plasmids16 
containing a TRP1 or a LEU2 cassette, respectively. For auto-activation tests (DB-X/Y vs. AD-empty), 
Y8800 (MATa) yeast cells were also transformed with a pDEST-AD-empty plasmid. Six standard Y2H 
controls were also transformed into yeast cells: 1) pDEST-AD-empty/pDEST-DB-empty, 2) pDEST-
AD-CBLB/pDEST-DB-GRB2, 3) pDEST-AD-XIAP/pDEST-DB-CASP9, 4) pDEST-AD-
empty/pDEST-DB-scGal4, 5) pDEST-AD-empty/pDEST-DB-WDR62, and 6) pDEST-AD-scUme6 
(a.a. 531-a.a. 836)/pDEST-DB. For each individual transformation, 0.3 to 1.5 µg of high-purity plasmid 
and 1 mL of a log phase-growth yeast cell culture (OD600 nm ~ 0.6-0.9) were used. The resulting 
transformants carrying pDEST-AD vectors (TRP1 cassette) or pDEST-DB vectors (LEU2 cassette) were 
spotted (8 µL per spot) onto solid synthetic complete media lacking tryptophan (SC-W) or leucine (SC-
L), respectively. After 3 days of incubation at 30°C, each transformant growing on solid SC-W or SC-L 
was picked by scratching the corresponding spot, and inoculated into a 96-well costar plate (Fisher 
Scientific/Corning, #07200720A) containing 160 µL of liquid SC-W or SC-L per well, respectively. 
Inoculated yeast cells were incubated overnight (15 to 18 hours), at 30°C and under shaking conditions 
(220 rpm). Haploid yeast were mated by inoculating 5 µL of transformed MATa Y8800 and 5 µL of 
transformed MATα Y8930 into a 96-well microplate containing 160 µL of YEPD medium (yeast extract, 
peptone, dextrose) per well. The exact same mating was done for the auto-activation tests (DB-X/Y-
containing cells mated with AD-empty-containing cells). Mating was obtained by growing cells 
overnight (15 to 18 hours), at 30°C and under shaking conditions (220 rpm). The diploid selection was 
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conducted by inoculating 10 µL of mated yeast cells into a 96-well microplate containing 160 µL of SC-
LW medium per well. Cells were incubated overnight (15 to 18 hours), at 30°C and under shaking 
conditions (220 rpm). Using a liquid handling robot, each diploid cell culture was then spotted in 
quadruplicate (1 µL/spot) onto two different solid media plates: 1) SC-LW, and 2) SC-LW lacking 
histidine and containing 1 mM of 3-Amino-1,2,4-triazole (3-AT) (SC-LWH, 1 mM 3-AT). The six 
controls described above were also spotted on each solid plate to validate composition of selective 
media (based on their known phenotypes on these media) and compare their growth rates to the ones of 
tested protein pairs. Plates were incubated for four days at 30°C and two days at room temperature 
before evaluating growth scores.  
 
Gaussia princeps complementation assay (GPCA). HEK293T cells were cultured as described for the 
mN2H assay version. For each protein, 100 ng of purified plasmid DNA was transfected into HEK293T 
cells in 96-well, flat-bottom, cell culture plates (Greiner Bio-One, #655083) supplemented with 
10%FBS in DMEM using polyethylenimine24. The DNA/PEI ratio (mass:mass) was 1:3. GPCA vectors 
carry the human cytomegalovirus (CMV) promoter and are maintained as high copy number with the 
human virus SV40 replication origin in mammalian cells. 24 hours after DNA transfection, the cell 
culture medium was removed, cells were gently washed with 150 µL pre-warmed 1x PBS, 40 µL of 
lysis buffer was then added per well, and cell lysis was performed under vigorous shaking of the plate 
for 20 minutes at 900 rpm. Luminescence was measured by auto-injecting 50 µL Renilla luciferase 
substrate (Renilla Luciferase Assay system, catalog No. E2820, Promega) per well and integrating light 
output for 4 seconds using a TriStar luminometer (Berthold). 
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Construction of C-terminal plasmids for GPCA. GPCA C1 and C2 vectors are based on two 
fragments of the humanized Gaussia princeps luciferase (herein referred as GLuc), similar to the GPCA 
N1 and N2 vectors24. Both GLuc fragments were linked to the C-terminal extremity of the tested 
proteins by a flexible hinge polypeptide of 20 amino acids, including the Gateway recombinational 
cloning sites. To normalize mRNA translation initiation, a consensus Kozak translation start sequence 
was added. Both constructs were carried by the same CMV driven mammalian expression vector (pCI-
neo derived, Promega) and were maintained as multi-copies within the cells via the presence of the 
SV40 replication origin. 
 
NanoLuc® Binary Technology (NanoBiT) assay. HEK293T cells were cultured as described for the 
mN2H assay version. For each protein, 100 ng of purified plasmid DNA was transfected into HEK293T 
cells grown in 96-well, flat-bottom, cell culture microplates (Greiner Bio-One, #655083). The DNA/PEI 
ratio (mass:mass) was 1:3 for the transfection. 24 hours later, 100 µL of the NanoLuc substrate 
(Promega, #N1110) were added to each well, plates were incubated for 3 minutes at room temperature, 
and luminescence output was measured using a TriStar luminometer (Berthold; 1 second integration 
time). 
 
Construction of Gateway-compatible plasmids for NanoBiT. The Gateway reading frame cassette 
was amplified by PCR, and polished with a PCR polishing kit (Agilent, # 200409) to generate blunt-end 
DNA. NanoBiT vectors (Promega, # N2014) with N- and C-terminus tagging configurations (NB 
MCS1, NB MCS2, NB MCS3, NB MCS4) were obtained from Promega, each containing an HSV-TK 
promoter for protein expression in mammalian cells and an ampicillin resistance marker for bacterial 
selection of transformed cells. Each plasmid DNA for NanoBiT vectors (NB MCS1-4) was digested 
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with a single-cut restriction enzyme (EcoRI for NB MCS1 and 2, and SacI for NB MCS3 and 4) at the 
multiple cloning sites (MCS). The linearized plasmid DNA was processed with the PCR polishing kit 
generating blunt-end DNA. Antarctic phosphatase (NEB, M0289S) was used to remove 5’-phosphates to 
reduce self-ligation background of the linearized vector. The ligation reaction was performed with T4 
DNA ligase (NEB, M0202S) joining the linearized NanoBiT vectors (NB MCS1-4) with the polished 
Gateway reading frame cassette. The ligated, Gateway compatible NanoBiT vectors (NanoBiT-GW-N1, 
-N2, -C1 and –C2) were introduced into One ShotTM ccdB survivalTM 2 T1R competent E. coli cells 
(Invitrogen, #A10460) via heat shock bacterial transformation, and selected on chloramphenicol-
containing LB agar plates. The sequences of constructed NanoBiT-GW vectors were examined by 
Sanger DNA sequencing. The final vectors contained correct sequences of the promoter, NanoBiT 
fragments, junctions, and Gateway cassette.  
 
Mammalian protein-protein interaction trap (MAPPIT) and Kinase substrate sensor (KISS) 
assays. HEK293T cells were cultured as described for the mN2H assay version. In both MAPPIT and 
KISS assays12,25, HEK293T cells were transfected with bait, prey and reporter plasmids applying a 
standard calcium phosphate transfection method. Luciferase activity was measured 48 hours after 
transfection using the Luciferase Assay System kit (Promega) on a Enspire luminometer (Perkin-Elmer). 
For MAPPIT, half of the cells were stimulated with erythropoietin (2 ng/mL; GenScript) 24 hours after 
transfection. For each tested pair in MAPPIT, the fold-induction value (signal from 2 stimulated culture 
wells divided by the signal from 2 unstimulated culture wells) was calculated. For KISS the average of 4 
culture wells was used. 
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Scoring hsPRS-v2 pairs. Data for each assay version performed in this study are presented in Source 
Data 1. All binary PPI experiments were independently performed three times. For the different 
versions of N2H experiments, the average signal of the three replicates was used to determine a raw 
luminescence value for each protein pair X/Y. Control experiments were performed similarly where 
protein X or Y fused to the NanoLuc fragment F1 or F2 was co-expressed with the matching NanoLuc 
fragment alone (X/empty or empty/Y). For each protein pair X-Y, we calculated a normalized 
luminescence ratio (NLR) corresponding to the raw luminescence value of the tested pair (X-Y) divided 
by the maximum luminescence value from one of the two controls (X-empty or empty-Y), as 
summarized in equation (1) below25. 
 NLR!!! = !"#$%&'(&%(&!!!!"#$%&% !"#$%&'(&%(& !!!"#$%  !" (!"#$%!!)   (1) 
 
To identify protein pairs that score positive at a threshold of no RRS detection, two criteria were 
considered: 1) NLRPRS > NLRHIGHEST RRS, and 2) NLRPRS > 1.0. All PRS pairs that did not meet these 
two criteria were not scored and therefore defined as not detectable in the corresponding assay version. 
The same analysis and criteria were applied for both KISS and MAPPIT assays. 
For GPCA and NanoBiT experiments, a PRS pair was scored positive if its corresponding raw 
luminescence signal (from the average of three independent experiments) was strictly higher than the 
RRS pair having the highest raw luminescence signal (from the average of three independent 
experiments). 
For Y2H assay, diploid yeast cells containing both, DB-X/Y bait and AD-Y/X prey plasmids, 
were spotted in quadruplicate on selective medium supplemented with 3-AT (SC-LWH, 3-AT). After 
titration of 3-AT, a minimal concentration of 1 mM was selected as no RRS pairs were detected for this 
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specific threshold12. In parallel, diploid yeast cells containing DB-X/Y bait and AD-empty prey vectors 
were also used to identify bait proteins that are auto-activators of the HIS3 selection marker. After 6 
days of culture, yeast growth was visually determined and scored from “0” (no growth) to “4” (strong 
growth) for both the DB-X/Y:AD-Y/X and DB-X/Y:AD-empty combinations. If the growth score was 
>0 for the DB-X/Y:AD-Y/X combination in at least two of the three experiments performed and was 
superior by at least 2 units to the one of DB-X/Y:AD-empty combination, a protein pair was scored 
positive. 
 
Construction of cumulative recovery plots. To plot the fraction of interaction recovered for n number 
of assays or assay versions, the recovery rate for each of the possible n combinations was calculated first 
(Supplementary Figs. 1c, 2d, 5a) and then averaged (Figs. 2b,d, 3f and Supplementary Fig. 5b). The 
error bars in Figs. 2b,d, 3f and Supplementary Fig. 5b indicate the standard deviation of the average.  
 
DATA AVAILABILITY 
The data supporting the findings from this study are included either in the manuscript and its associated 
supplementary files, or can be extracted from the original referenced publications. The protein-protein 
interaction data have been deposited to the IntAct database (https://www.ebi.ac.uk/intact/), and will be 
publicly available with PubMed ID upon publication. All data are also available from the authors upon 
request. N2H plasmids and their corresponding maps were deposited to the Addgene plasmid repository 
(https://www.addgene.org/Marc_Vidal/). 
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FIGURE LEGENDS 
Figure 1 | A framework to combine assays and maximize overall detection. (a) Combining multiple 
assays and/or assay versions to increase detection under maximum specificity. (b) A multi-dimensional 
space of experimental conditions for each binary PPI assay. (c) Comparing combinations of different, 
distinct assays (left) to combinations of multiple assay versions explored by the single, highly versatile 
NanoLuc 2-hybrid (N2H) system (right). 
 
Figure 2 | Recovery of positive control PRS pairs by multiple assays or assay versions. (a) Fractions 
of hsPRS-v1 pairs recovered by ten well-established assays when an identical threshold of no hsRRS-v1 
pairs scoring positive is applied. (b) Cumulative hsPRS-v1 recovery rates when assays in (a) are 
combined (individual data points are displayed in Supplementary Fig. 1c). (c) Fractions of hsPRS-v2 
pairs recovered by different versions of GPCA, KISS, MAPPIT, Y2H and NanoBiT when an identical 
threshold of no hsRRS-v2 pairs scoring positive is applied. Horizontal shaded blue area indicates the 
average recovery rate ± S.D. for GPCA, KISS, MAPPIT and Y2H versions. (d) Cumulative hsPRS-v2 
recovery rates when versions of GPCA, KISS, MAPPIT and Y2H presented in (c) are combined 
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(individual data points are displayed in Supplementary Fig. 2d). Error bars indicate standard errors of 
proportions (a,c) or standard deviations (b,d).  
 
Figure 3 | Development of the highly versatile N2H assay. (a) Determination of a new split site for 
NanoLuc. Dark blue bar and red arrow indicate the selected NanoLuc fragments. RLU=relative 
luminescence units. NLuc=NanoLuc. Blank control corresponds to reagents without any NanoLuc 
fragment. (b) Tripartite promoter and specific activities of selected N2H fragments, F1 and F2, 
normalized to full-length NanoLuc when expressed in mammalian cells (mN2H; orange), in yeast 
(yN2H; purple), or in vitro (vN2H; gray), from the same plasmid. For “empty”: no protein or fragment 
was expressed. CMV: cytomegalovirus; HSV-TK: herpes simplex virus-thymidine kinase; UAS: 
upstream activating sequence; IRES: internal ribosome entry site. Red arrow displayed on NanoLuc 
structure (PDB: 5IBO) indicates the cleavage area. (c) Reproducibility of N2H assay in three expression 
environments (mN2H, yN2H and vN2H) for the N1N2 tagging configuration. Each triangle in the 
different graphs represents a single tested protein pair. (d) Normalized luminescence signals for 12 
versions of N2H benchmarked against hsPRS-v2 and hsRRS-v2. Blue squares and purple circles 
indicate PRS and RRS pairs, respectively. The threshold of no RRS pair scoring positive is indicated 
(horizontal line) for each assay version. (e) Fraction of hsPRS-v2 pairs recovered by 12 N2H assay 
versions when none of the hsRRS-v2 pairs are scored positive, corresponding to the thresholds displayed 
in (d). Horizontal shaded blue area indicates the average recovery rate ± S.D. for all assay versions 
reported in Fig. 2c. (f) Cumulative hsPRS-v2 recovery rates when versions of N2H presented in (e) are 
combined (individual data points are displayed in Supplementary Fig. 5a). Error bars indicate standard 
deviations (b,f) or standard errors of proportions (e). 
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Figure 4 | Invested resources for various combinations of binary PPI assays and PRS detection 
rates. Numbers of individual components required to achieve maximal PRS detections are indicated for 
different combinations of assays and assay versions. PRS recovery rates presented in Fig. 4e correspond 
to those found in Fig. 2b (published), Supplementary Fig. 5b (non-N2H) and Fig. 3f (N2H). Except for 
Y2H-N1C2, Y2H-C1C2 and Y2H-C1N2 for which unambiguous titrations could not be obtained from 
the original study28, all published assay versions benchmarked against hsPRS-v1 and hsRRS-v1 were 
used (Fig. 2a, Supplementary Table 1).    
 
Figure 5 | Impact of permuting assay parameters on binary PPI detection. (a), (b), (c) PPIs detected 
by permuting (a) protein orientations in Y2H and MAPPIT, (b) tagging configurations in KISS (only 
two versions tested), NanoBiT, GPCA, mN2H, yN2H and vN2H, and (c) protein expression 
environments in N2H. Error bars in (a-c) indicate standard deviations. 
 
Figure 6 | Complementarity of different assay versions. Detection of individual hsPRS-v2 pairs (left 
panel) by the assay versions used in Fig. 5a-c, under conditions where none of the hsRRS-v2 pairs (right 
panel) are scored positive. Detected hsPRS-v2 pairs are indicated by blue squares: light blue 
corresponds to individual assay versions and dark blue to the union of assay versions into distinct assays 
or combinations of assays. Identity of pairs can be found in Supplementary Table 4. 
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